- 18luck新利网站utf-82025-07-26 13:46:092025-07-26 13:46:092024-12-05]]>2024-12-092024-12-022024-10-09]]>2024-12-062023-04-142024-10-282024-10-172024-07-192024-07-152024-07-042024-07-042024-06-062024-06-052024-04-262024-05-102024-03-282024-04-09Tumor microenvironment (TME) primarily contributes to resistance in clinical antineoplastic treatment. In non-small-cell lung cancers (NSCLCs), the frequently mutated KRAS oncogene (mainly at the KRASG12C position) promotes tumor progression. The interdisciplinary research team at NCKU has successfully nano-formulated the small-molecular drug Sitravatinib (currently undergoing clinical trials internationally) using polymeric nanoparticles to form the novel nano-drug Au@PSMA-Sit. In the murine lung cancer model bearing KRASG12C mutant TME, Au@PSMA-Sit nanoparticles exhibit outstanding antitumor efficacy, requiring a lower therapeutic dosage (1/10) of sitravatinib. These experimental achievements were published in the authoritative international journal Nano Today in February 2024 with an impact factor of 17.4. Polymeric nano-formulation of spectrum selective RTK inhibitor strengthens anti-cancer effects via immune remodeling by endoplasmic reticulum stress-modulating mitochondrial metabolism
]]>2024-02-26